Elanix Biotechnologies AG (FRA:ELN) ROCE % : -14.51% (As of Dec. 2018)

View and export this data going back to . Start your Free Trial

What is Elanix Biotechnologies AG ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Elanix Biotechnologies AG's annualized ROCE % for the quarter that ended in Dec. 2018 was -14.51%.

Elanix Biotechnologies AG ROCE % Historical Data

The historical data trend for Elanix Biotechnologies AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elanix Biotechnologies AG ROCE % Chart

Elanix Biotechnologies AG Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

ROCE %

Get a 7-Day Free Trial

-5.25

-28.35

-10.84

-32.41

Elanix Biotechnologies AG Semi-Annual Data
	Dec08	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18
ROCE %	Get a 7-Day Free Trial															-13.12	-18.07	-25.48	-54.18	-14.51

Elanix Biotechnologies AG ROCE % Calculation

Elanix Biotechnologies AG's annualized ROCE % for the fiscal year that ended in Dec. 2018 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2018 )		(A: Dec. 2017 )		(A: Dec. 2018 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2018 )		(A: Dec. 2017 )		(A: Dec. 2018 )
	=	-3.458	/	( ( (2.466 - 1.758)	+	(1.078 - 2.306) )	/ 2 )
	=	-3.458	/	( (0.708	+	-1.228)	/ 2 )
	=	-3.458	/	-0.26
	=	1,330.00 %

Elanix Biotechnologies AG's ROCE % of for the quarter that ended in Dec. 2018 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2018 )		(Q: Jun. 2018 )		(Q: Dec. 2018 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2018 )		(Q: Jun. 2018 )		(Q: Dec. 2018 )
	=	-1.35	/	( ( (21.569 - 1.732)	+	(1.078 - 2.306) )	/ 2 )
	=	-1.35	/	( ( 19.837	+	-1.228 )	/ 2 )
	=	-1.35	/	9.3045
	=	-14.51 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2018) EBIT data.

Elanix Biotechnologies AG (FRA:ELN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Elanix Biotechnologies AG ROCE % Related Terms

Thank you for viewing the detailed overview of Elanix Biotechnologies AG's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Elanix Biotechnologies AG (FRA:ELN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elanix Biotechnologies AG (FRA:ELN) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Street-4, Georg-Glock, c/o HEUKING KÜHN LÜER WOJTEK, Dusseldorf, NW, DEU, 40474

Website

https://www.elanixbiotechnologies.ch

Elanix Biotechnologies AG is a tissue regeneration company. It develops and commercializes products for acute wound care, dermatological and gynecological applications as well as providing cell technology services. The company's operating segment include Regenerative Medicine and Cosmetic ointments. It generates maximum revenue from the Cosmetic ointments segment. Geographically, it derives a majority of revenue from Switzerland and also has a presence in the EU, and Taiwan.

Elanix Biotechnologies AG (FRA:ELN) Headlines

No Headlines